Ocugen (FRA:2H51) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 09, 2026)


FRA:2H51 Ocugen Inc FRA:2H51
20 GF Score
Price €1.31
GF Value €0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocugen Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ocugen's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:2H51 vs STRO, NGNE, CBIO: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Ocugen's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocugen Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Ocugen's Margin of Safety % (DCF FCF Based) falls into.


FRA:2H51
20GF Score
Ocugen Inc FRA:2H51
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ocugen (FRA:2H51) Overvalued in 2026?

Based on GuruFocus' analysis, Ocugen stock appears to be overvalued. The current stock price of €1.31 is trading 92.6% above its estimated GF Value™ of €0.68. GuruFocus considers Ocugen to be Significantly Overvalued.

Key valuation signals for FRA:2H51:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €0.68 vs. price of €1.31 (92.6% above fair value)
  • GF Score™: 20/100 with 4 warning signs

No single metric tells the full story. See the FRA:2H51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocugen Business Description

Address 11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
20GF Score

Get the complete analysis for FRA:2H51

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price
€0.68
GF Value